Please login to the form below

Not currently logged in
Email:
Password:

Former Boehringer Ingelheim US CEO joins Inotek

Martin Carroll elected as chairman of the board

US-based Inotek Pharmaceuticals has appointed Martin Carroll to its board of directors and elected him as chairman of the board.

He will succeed current chairman Argeris Karabelas upon his resignation from the board, which takes effect on 23 June.

Caroll brings over 35 years of experience in the pharmaceutical industry to the board, including 25 years at Merck & Co. where he held increasingly senior roles, finally as executive vice president, customer marketing and sales.

After leaving Merck & Co in 2001, Carroll served as president and chief executive officer of Boehringer Ingelheim in the US, before becoming its head of global strategy.

He currently serves as a member of the board of directors at Catalent, Mallinckrodt Pharmaceuticals and TherapeuticsMD.

David Southwell, president and chief executive officer of Inotek, said: “Mr Carroll has a track record of success as a pharmaceutical industry leader and will bring operational experience in many areas including R&D, manufacturing and sales.

“His diverse expertise will be invaluable to us as we further develop Inotek into a leading ophthalmology company.”

Carroll said: “The Company's world class leadership team and board of directors demonstrates their commitment to bring novel ocular therapies to market for patients.

“I look forward to working closely with Inotek's management and board.”

11th April 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics